Results 151 to 160 of about 15,819,940 (362)
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
25 million people internally displaced by violence worldwide [PDF]
Global IDP Project
doaj
Book Review: Jacob Steiner's Vorlesungen über synthetische Geometrie. Zweiter Theil: Die Theorie der Kegelschnitte gestützt auf projective Eigenschaften [PDF]
Isabel Maddison
openalex +1 more source
Travel Disruption: Three Case Studies [PDF]
This report draws together the findings of three studies of travel disruption and its impacts on travellers: the volcanic ash cloud which disrupted aviation in Europe in 2010, the loss of road bridges between November 2009 and April 2010 at Workington ...
Disruption Project, Guiver, Jo W
core
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha +10 more
wiley +1 more source
Atolls visited during the first year of the Pacific Islands Rat Ecology Project [PDF]
Joe T. Marshall
openalex +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
On Certain Projective Generalizations of Metric Theorems, and the Curves of Darboux and Segre
Gabriel M. Green
openalex +1 more source

